Generated by AI
Indaptus Therapeutics Inc. is a clinical-stage biotechnology company focused on developing immunotherapy products for cancer and viral infections. The company’s current work centers on its Decoy platform, a proprietary system designed to activate multiple components of the innate and adaptive immune system while aiming to reduce systemic toxicity. Its lead candidate, Decoy20, is being developed for a range of oncology and infectious disease applications, including solid tumors and chronic viral infections. Indaptus Therapeutics Inc. operates in the biopharmaceutical sector, where it contributes to research-driven drug development with an emphasis on novel immune-activating approaches. Based in New York, the company is primarily engaged in preclinical and clinical-stage development activities rather than commercial product sales.
WebsiteThree Columbus Circle
New York, NY, 10019
United States
The latest articles about INDP.
Tipranks Press Release.
Summary of Sep 15's posts. Generated by AI.
Summary of Jun 11's posts. Generated by AI.
Detailed price information for Indaptus Therapeutics Inc (INDP-Q) from The Globe and Mail including charting and trades.
Summary of Dec 24's posts. Generated by AI.
Summary of Sep 9's posts. Generated by AI.
Investors talking about INDP also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.